Literature DB >> 23582968

Long-term pulmonary outcomes of patients with bronchopulmonary dysplasia.

Anita Bhandari1, Sharon McGrath-Morrow.   

Abstract

Bronchopulmonary dysplasia (BPD) is the commonest cause of chronic lung disease in infancy. The incidence of BPD has remained unchanged despite many advances in neonatal care. BPD starts in the neonatal period but its effects can persist long term. Premature infants with BPD have a greater incidence of hospitalization, and continue to have a greater respiratory morbidity and need for respiratory medications, compared to those without BPD. Lung function abnormalites, especially small airway abnormalities, often persist. Even in the absence of clinical symptoms, BPD survivors have persistent radiological abnormalities and presence of emphysema has been reported on chest computed tomography scans. Concern regarding their exercise tolerance remains. Long-term effects of BPD are still unknown, but given reports of a more rapid decline in lung function and their suspectibility to develop chronic obstructive pulmonary disease phenotype with aging, it is imperative that lung function of survivors of BPD be closely monitored.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23582968     DOI: 10.1053/j.semperi.2013.01.010

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  39 in total

1.  Respiratory morbidity, lung function and fitness assessment after bronchopulmonary dysplasia.

Authors:  M Praprotnik; I Stucin Gantar; M Lučovnik; T Avčin; U Krivec
Journal:  J Perinatol       Date:  2015-10-15       Impact factor: 2.521

2.  Bronchopulmonary Dysplasia and Pulmonary Hypertension. The Role of Smooth Muscle adh5.

Authors:  Thomas M Raffay; Koby Bonilla-Fernandez; Anjum Jafri; Ramadan B Sopi; Laura A Smith; Feifei Cui; Maureen O'Reilly; Rongli Zhang; Craig A Hodges; Peter M MacFarlane; Gail Deutsch; Richard J Martin; Benjamin Gaston
Journal:  Am J Respir Cell Mol Biol       Date:  2021-07       Impact factor: 6.914

3.  Pharmacological options for BPD prevention: steps for better clinical trial design.

Authors:  R M Viscardi
Journal:  J Perinatol       Date:  2014-09       Impact factor: 2.521

Review 4.  Respiratory distress in the newborn.

Authors:  Suzanne Reuter; Chuanpit Moser; Michelle Baack
Journal:  Pediatr Rev       Date:  2014-10

5.  Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium.

Authors:  Rita M Ryan; Roberta L Keller; Brenda B Poindexter; Carl T D'Angio; Pamela A Shaw; Scarlett L Bellamy; Paul E Moore; Christopher McPherson; James M Greenberg
Journal:  J Pediatr       Date:  2019-03-08       Impact factor: 4.406

6.  Magentic Resonance Imaging Evaluation of Regional Lung Vts in Severe Neonatal Bronchopulmonary Dysplasia.

Authors:  Kara R Gouwens; Nara S Higano; Kaitlyn T Marks; Julia N Stimpfl; Erik B Hysinger; Jason C Woods; Paul S Kingma
Journal:  Am J Respir Crit Care Med       Date:  2020-10-01       Impact factor: 21.405

7.  Response to bronchodilators in very preterm infants with evolving bronchopulmonary dysplasia.

Authors:  Daniel K Morrow; Diane Schilling; Cindy T McEvoy
Journal:  Res Rep Neonatol       Date:  2015-12-02

8.  Quantitative Magnetic Resonance Imaging of Bronchopulmonary Dysplasia in the Neonatal Intensive Care Unit Environment.

Authors:  Laura L Walkup; Jean A Tkach; Nara S Higano; Robert P Thomen; Sean B Fain; Stephanie L Merhar; Robert J Fleck; Raouf S Amin; Jason C Woods
Journal:  Am J Respir Crit Care Med       Date:  2015-11-15       Impact factor: 21.405

Review 9.  Stem Cell Therapy in Neonatal Diseases.

Authors:  Ciprian P Gheorghe; Vineet Bhandari
Journal:  Indian J Pediatr       Date:  2015-03-26       Impact factor: 1.967

Review 10.  The Natural History of Bronchopulmonary Dysplasia: The Case for Primary Prevention.

Authors:  Cindy T McEvoy; Judy L Aschner
Journal:  Clin Perinatol       Date:  2015-10-01       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.